The explanation for the findings is that immunomodulatory therapies and inflammation due to vemurafenib trigger the patient’s antitumor immunity, inducing the systemic release of cytokines and activation of natural killer (NK) and cytotoxic T lymphocytes.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}